trigger finger injections


A study from Missouri assessed the longterm outcome of a single corticosteroid injection for a trigger finger (see trigger finger injection j bone surg 2014​ in dropbox, or J Bone Joint Surg Am 2014 Nov 19; 96:1849​). they assessed 366 patients who had a first injection and followed a minimum of 5 years. 

background: 
    --trigger fingers are pretty common. lifetime risk estimated in general population of 2.6%, 4-10% in diabetics
    --and, from my patients, pretty uncomfortable and affects daily functioning

results:
--66% female, average age 59 yo, 44% with multiple trigger fingers, 24% with diabetes. majority had symptom of "catching" but able to actively extend the digit​.
--their protocol was injecting the A1 pulley area with methylprednisolone 40mg/cc, 1cc, and lidocaine without epinephrine 1%, 0.5 to 1 cc. 
--primary outcome (which was to not get subsequent injection or surgical release) of the affected digit was in 45% of patients, with a 56% success rate in females (vs 35% in males), and approx 38% in males and females with multiple trigger fingers. 
--of the treatment failures, 64% got another injection, 33% had surgical release
--84% of treatment failures were in the first 2 years after injection (ie, those who lasted 2 years did well longterm)
--other studies have found even higher longish term success rates (one with 92% for trigger thumbs, another with 72%)

so, a few comments:
--these are really easy injections. i use just 1/2 cc of triamcinolone 40mg/cc plus 1/2 cc of lidocaine 1% and inject with a 30 gauge short needle (though it still hurts: thick skin and too many nerves), injecting where i palpate the nodule, which is right at the A1 pulley entrance, close to the MCP joint on the volar surface). and, though i have not looked at the success rate rigorously, i am confident that in the dozens i have injected, at least  90% have had really good responses and it is pretty rare that patients come back for more. and, even if the injection lasted only 1 year, that's a lot of relief for the patient, and re-injections (done rarely by me) have also been successful.  after 2 injections, i would suggest surgical intervention.
--the injections take about 3 minutes and are the easiest of my patient visits (a thousand times easier than the more frequent patient with uncontrolled diabetes, hypertension, depression, domestic violence.......). and, as an aside, an orthopedic surgeon doing this injection probably gets as much $$ as my health center collects for 5 visits of my more difficult patients...

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

HDL a negative risk factor? or cholesterol efflux??

Although the data on HDL being protective of atherosclerotic disease is pretty consistent, there are negative studies, and the data on medications which dramatically improve HDL levels (eg, the cholesteryl ester transfer protein --CETP --inhibitors, such as torcetrapib) are clinically disappointing. there have been several explanations for this. for example, some HDL particles are "pro-inflammatory" and elicit an atherosclerotic response (which may be related to apolipoprotein C-III). a new article in NEJM highlights another angle -- that the issue is not the HDL number, but HDL's functionality in the reverse transport of cholesterol, as measured by the cholesterol efflux capacity (see  lipids HDL efflux capacity vs amt NEJM 2014 in dropbox, or  DOI: 10.1056/NEJMoa1409065). This article looks at the Dallas Heart Study, where they measured HDL levels, HDL particle concentrations, and cholesterol efflux capacity in 2924 adults free of cardiovascular disease and followed p
Read more

Drug company shenanigans: narcolepsy drug

I have not done a blog for a long time on drug company shenanigans. So it is my great pleasure to bring up a brand-new drug company approach to garner huge amounts of money (see  https://www.nytimes.com/2023/02/28/business/jazz-narcolepsy-avadel-patents.html?smid=nytcore-ios-share&referringSource=articleShare  ).  Based on an article by  Rebecca Robbins of the New York Times, who has written several articles on drug company excesses   As background, this will be my 42 nd  such blog: for the array, see  https://bucommunitymed.wpengine.com/page/4/?s=drug+company+shenanigans   Th e drug company  approach  this time  to extending  their  patents has a few “interesting” angles: -- this is a medication manufactured by Jazz Pharmaceuticals to treat narcolepsy: there are 2 versions: Xyrem and Xywav (Xywav has less sodium, so is marketed to those who should be on a low sodium diet). These meds are basically derivatives of gammahydroxybutyric acid (GHB)      -- the drug actually has a pretty
Read more

UPDATE: ASCVD risk factor critique

  I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:              -- there is very clear evidence that there are many individual risk factors that are associated with increased risk of a cardiovascu
Read more